Aptar Digital Health Expands Oncology Clinical Advisory Board

Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, today announced the expansion of its Oncology Clinical Advisory Board. Comprised of leading clinical, oncology and digital experts from across a wide range of cancer specialties, this newly formed Clinical Advisory Board will help provide critical review and scientific guidance to Aptar Digital Health on the development of its evidence-based medical algorithms.

The new members of the Aptar Digital Health Oncology Clinical Advisory Board include:

  1. Adam DICKER, MD, PhD – Chair and Professor of Radiation Oncology, Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA
  2. Marilyn HUANG, MD – Professor of Gynecologic Oncology, Director of Translational Gynecologic Oncology Research, University of Miami, Miami, FL
  3. Mario LACOUTURE, MD – Director of the Oncodermatology Program, Memorial Sloan Kettering Cancer Center, New York, NY
  4. Aditi U. JOSHI, MD, MSc – Emergency Medicine Physician, Telehealth and Digital Health Expert, US.

These members are welcomed by existing members of the Board, including:

Paolo BOSSI, MD, Prof. – Associate Professor, Medical Oncology, University of Brescia and ASST Spedali Civili, Brescia, Italy

Karin JORDAN, MD, Prof. – Head of Department of Hematology, Oncology and Palliative Care​, Ernst von Bergmann Clinic, Potsdam, Germany ​
Matti AAPRO, MD – Dean of Multidisciplinary Oncology Institute, Genolier Cancer Centre Switzerland

Guido CAVALETTI, MD – Head of the Neuroimmunology Center, S. Gerardo Hospital, Monza, Italy

Gregory LIP, MD – Cardio-Oncology Expertise, Liverpool Heart & Chest Hospital, Liverpool, UK.

Pere GASCON, MD, PhD – Chief of Medical Oncology and Scientific Coordinator, Hospital Clínic, Barcelona, Spain.

“We are pleased to strengthen our Clinical Advisory Board and to welcome our new members,” commented Pierre Leurent, President, Aptar Digital Health. “Their broad medical expertise will allow us to have a deeper knowledge and expand our global vision of the clinical practice for multiple types of cancer.”

Genevieve D’Orsay, MD, Chief Medical Officer at Aptar Digital Health added, “The Clinical Advisory Board contributes to the design of our clinical algorithms that support patients in the management of treatment-related symptoms. The contribution of each member is key to ensuring our solutions address a clinical need. Our Advisory Board also guides Aptar Digital Health in our clinical strategy decision, including the deployment of clinical studies.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.